We are live on ! Find out more
SONN

Sonnet BioTherapeutics
SONN

Delisted

SONN was delisted on the 2nd of December, 2025.

Back to rankings

1 hedge funds and large institutions have $294K invested in Sonnet BioTherapeutics in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

38% less capital invested

Capital invested by funds: $474K → $294K (-$180K)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$33K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
1
Perkins Capital Management
Minnesota
$110K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$51K – – –
IC
3
Intersect Capital
California
$31K – – –
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$29K – – –
BlackRock
5
BlackRock
New York
$27K – – –
AG
6
Advisor Group
Arizona
$21K – – –
Bank of America
7
Bank of America
North Carolina
$13K – – –
SCM
8
Stumpf Capital Management
Arizona
$5K – – –
UBS Group
9
UBS Group
Switzerland
$4K – – –
QCIG
10
Quad-Cities Investment Group
Iowa
$3K – – –
VF
11
Virtu Financial
New York
– -$33K – –

SONN Hedge Fund Activity: Q3 2018 in Review

1 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q3 2018, worth a combined $294K — down 38% from $474K a quarter earlier.

Fund positioning in SONN was balanced in Q3 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Virtu Financial, cutting an estimated $33K.

  • 1 institutional investor held Sonnet BioTherapeutics (SONN) as of Q3 2018, unchanged from Q2 2018.
  • Funds reported $294K of Sonnet BioTherapeutics stock for Q3 2018, down 38% quarter-over-quarter.
  • 0 funds opened new Sonnet BioTherapeutics positions in Q3 2018 and 0 closed out.
  • The largest Sonnet BioTherapeutics seller in Q3 2018 was Virtu Financial, an estimated $33K sold.

Based on aggregated 13F filings for Q3 2018.